Citrate-free Taltz now available

A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier this year, Eli Lilly and Company announced in a press release.

The new formulation of Taltz (ixekizumab) 80 mg/mL injection showed significantly reduced injection site pain and an 86% decrease in VAS compared with the original formulation.

Taltz is approved for adults and children with severe plaque psoriasis, adults with active psoriatic arthritis, active ankylosing spondylitis and active non-radiographic axial spondylarthritis.

“Today is an exciting milestone for the nearly 30 million people around the world who live with the challenging symptoms of these autoimmune diseases that affect the skin and joints,” April W. Armstrong, MD, MPH, professor of dermatology and associate dean of clinical research, Keck School of Medicine at the University of Southern California, said in the release. “In my six years of prescribing Taltz, I’ve seen firsthand the significant impact Taltz has had for patients across multiple indications. The availability of Taltz as a citrate-free formulation represents an important advance in patient care that will allow more patients to experience less injection-site pain.”

A new prescription is not needed for patients already receiving therapy with Taltz. The new formulation will be shipped across the United States with widespread availability expected by the end of August. Additionally, the European Medicines Agency approved the citrate-free version of the drug in late 2021.